259 related articles for article (PubMed ID: 23868457)
21. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Miyaji T; Iioka Y; Kuroda Y; Yamamoto D; Iwase S; Goto Y; Tsuboi M; Odagiri H; Tsubota Y; Kawaguchi T; Sakata N; Basch E; Yamaguchi T
J Patient Rep Outcomes; 2017; 1(1):8. PubMed ID: 29757296
[TBL] [Abstract][Full Text] [Related]
22. Asking the right questions to get the right answers: using cognitive interviews to review the acceptability, comprehension and clinical meaningfulness of patient self-report adverse event items in oncology patients.
Holch P; Warrington L; Potrata B; Ziegler L; Hector C; Keding A; Harley C; Absolom K; Morris C; Bamforth L; Velikova G
Acta Oncol; 2016; 55(9-10):1220-1226. PubMed ID: 27551774
[TBL] [Abstract][Full Text] [Related]
23. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR
Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
[TBL] [Abstract][Full Text] [Related]
25. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
Atkinson TM; Ryan SJ; Bennett AV; Stover AM; Saracino RM; Rogak LJ; Jewell ST; Matsoukas K; Li Y; Basch E
Support Care Cancer; 2016 Aug; 24(8):3669-76. PubMed ID: 27260018
[TBL] [Abstract][Full Text] [Related]
26. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
[TBL] [Abstract][Full Text] [Related]
27. Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.
Sandler KA; Mitchell SA; Basch E; Raldow AC; Steinberg ML; Sharif J; Cook RR; Kupelian PA; McCloskey SA
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):44-52. PubMed ID: 30102201
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
29. A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy.
Christiansen MG; Pappot H; Jensen PT; Mirza MR; Jarden M; Piil K
J Patient Rep Outcomes; 2023 Jul; 7(1):72. PubMed ID: 37462855
[TBL] [Abstract][Full Text] [Related]
30. Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.
Lee MK; Basch E; Mitchell SA; Minasian LM; Langlais BT; Thanarajasingam G; Ginos BF; Rogak LJ; Mendoza TR; Bennett AV; Schrag D; Mazza GL; Dueck AC
Qual Life Res; 2023 Jul; 32(7):2047-2058. PubMed ID: 36897529
[TBL] [Abstract][Full Text] [Related]
31. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.
Albaba H; Barnes TA; Veitch Z; Brown MC; Shakik S; Su S; Naik H; Wang T; Liang M; Perez-Cosio A; Eng L; Mittmann N; Xu W; Howell D; Liu G
Oncologist; 2019 Nov; 24(11):e1219-e1227. PubMed ID: 31409744
[TBL] [Abstract][Full Text] [Related]
32. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
[TBL] [Abstract][Full Text] [Related]
33. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Basch E; Dueck AC; Rogak LJ; Minasian LM; Kelly WK; O'Mara AM; Denicoff AM; Seisler D; Atherton PJ; Paskett E; Carey L; Dickler M; Heist RS; Himelstein A; Rugo HS; Sikov WM; Socinski MA; Venook AP; Weckstein DJ; Lake DE; Biggs DD; Freedman RA; Kuzma C; Kirshner JJ; Schrag D
JAMA Oncol; 2017 Aug; 3(8):1043-1050. PubMed ID: 28208174
[TBL] [Abstract][Full Text] [Related]
34. Supporting quality and patient safety in cancer clinical trials.
Badalucco S; Reed KK
Clin J Oncol Nurs; 2011 Jun; 15(3):263-5. PubMed ID: 21624861
[TBL] [Abstract][Full Text] [Related]
35. Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Schroeder KM; Rizzieri T; Lion RR; Mtenga N; Gisiri M; McFatrich M; Reeve BB
J Patient Rep Outcomes; 2023 Jun; 7(1):56. PubMed ID: 37306774
[TBL] [Abstract][Full Text] [Related]
36. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
[TBL] [Abstract][Full Text] [Related]
37. Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development.
Xia H; Booth BP; Wang Y; Fan C; Bhatnagar V; Kluetz P; Fourie Zirkelbach J
J Patient Rep Outcomes; 2023 Nov; 7(1):116. PubMed ID: 37975967
[TBL] [Abstract][Full Text] [Related]
38. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
[TBL] [Abstract][Full Text] [Related]
39. Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation.
Kirsch M; Mitchell SA; Dobbels F; Stussi G; Basch E; Halter JP; De Geest S
Eur J Oncol Nurs; 2015 Feb; 19(1):66-74. PubMed ID: 25190633
[TBL] [Abstract][Full Text] [Related]
40. PROceeding With the Patient-Reported Outcomes (PROs) Version of the Common Terminology Criteria for Adverse Events.
Movsas B
JAMA Oncol; 2015 Nov; 1(8):1059-60. PubMed ID: 26270250
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
